Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H20N2O2.C4H8O2 |
Molecular Weight | 324.4152 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(O)=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
InChI
InChIKey=OIMQCNMGAZWCPW-UHFFFAOYSA-N
InChI=1S/C13H20N2O2.C4H8O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;1-3(2)4(5)6/h5-8H,3-4,9-10,14H2,1-2H3;3H,1-2H3,(H,5,6)
Molecular Formula | C4H8O2 |
Molecular Weight | 88.1051 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C13H20N2O2 |
Molecular Weight | 236.3101 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine. Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6082561 | http://www.abcam.com/procaine-hydrochloride-ab120865.html
Curator's Comment: Crosses the blood-brain barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
60.0 nM [IC50] | |||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8531111 |
50.0 µM [IC50] | ||
Target ID: CHEMBL4787 |
|||
Target ID: CHEMBL2411 |
1.7 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Procaine Approved UseProcaine is a local anesthetic. Procaine causes loss of feeling (numbness) of skin and mucous membranes.
Procaine is used as an injection during surgery and other medical and dental procedures. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/573562/ |
60 mg/kg single, intravenous dose: 60 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: Page: p.304 |
healthy, 72.8 n = 119 Health Status: healthy Condition: Age-related decline Age Group: 72.8 Sex: M+F Population Size: 119 Sources: Page: p.304 |
Disc. AE: Systemic lupus erythematosus synd... AEs leading to discontinuation/dose reduction: Systemic lupus erythematosus synd (0.84%) Sources: Page: p.304 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Systemic lupus erythematosus synd | 0.84% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: Page: p.304 |
healthy, 72.8 n = 119 Health Status: healthy Condition: Age-related decline Age Group: 72.8 Sex: M+F Population Size: 119 Sources: Page: p.304 |
PubMed
Title | Date | PubMed |
---|---|---|
[Drug allergy among patients suffering from nasal polyps]. | 2001 |
|
Pathways involved in RGD-mediated calcium transients in mature bovine oocytes. | 2001 |
|
Swelling of capillary endothelial cells and cardiomyocytes in the ischaemic myocardium of artificially arrested canine hearts. | 2001 |
|
Effect of posterior hypothalamic injection of procaine on the hippocampal theta rhythm in freely moving cats. | 2001 |
|
[Prognosis and criteria of recovered motility of one of the vocal cords in the middle position as a result cordectomy]. | 2001 |
|
From cocaine to ropivacaine: the history of local anesthetic drugs. | 2001 Aug |
|
Supraventricular ectopics and supraventricular tachycardia following injection of subconjunctival Mydricaine No. 2. | 2001 Aug |
|
Calcification in the planula and polyp of the hydroid Hydractinia symbiolongicarpus (Cnidaria, Hydrozoa). | 2001 Aug |
|
Effect of sub-Tenon's and peribulbar anesthesia on intraocular pressure and ocular pulse amplitude. | 2001 Aug |
|
Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. | 2001 Dec |
|
From the Centers for Disease Control and Prevention. Recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. | 2001 Dec 5 |
|
Ion-transfer voltammetry of local anesthetics at an organic solvent/water interface and pharmacological activity vs. ion partition coefficient relationship. | 2001 Jan |
|
Determination of apparent binding constants of drugs by capillary electrophoresis using beta-cyclodextrin as ligand and three different linear plotting methods. | 2001 Jul 27 |
|
Common solvent toxicity: autoxidation of respiratory redox-cyclers enforced by membrane derangement. | 2001 Jul-Aug |
|
Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. | 2001 Nov |
|
Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. | 2001 Nov 16 |
|
[Increase in brain activity of the carp Cyprinus carpio during visual deafferentation]. | 2001 Nov-Dec |
|
[Investigation on the mechanisms of leukocyte alteration in patients with intolerance to some drugs (with novocaine as a model)]. | 2001 Nov-Dec |
|
Santayana's prophecy fulfilled. | 2001 Nov-Dec |
|
[Interactions of histamine and glucocorticoids with nerve structures of respiration passages]. | 2001 Oct |
|
[Infusion therapy with procaine in acute tinnitus]. | 2001 Oct |
|
Optimisation and validation of a capillary electrophoresis method for the simultaneous determination of diazepam and otilonium bromide. | 2001 Oct |
|
[Myasthenia gravis]. | 2001 Oct |
|
Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. | 2001 Oct |
|
[Treatment of animals with acute and/or chronic complaints by electric stimulation therapy]. | 2001 Oct 15 |
|
Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats. | 2001 Sep |
|
Evidence that spinal segmental nitric oxide mediates tachyphylaxis to peripheral local anesthetic nerve block. | 2001 Sep |
|
Topical anesthesia with or without propofol sedation versus retrobulbar/peribulbar anesthesia for cataract extraction: prospective randomized trial. | 2001 Sep |
|
Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. | 2001 Sep 18 |
|
[Allergic alteration of leukocytes in patients with drug intolerance]. | 2001 Sep-Oct |
|
Oxybuprocaine induces a false-positive response in immunochromatographic SAS Adeno Test. | 2002 Apr |
|
Intrapericardial procaine affects volume expansion-induced fos immunoreactivity in unanesthetized rats. | 2002 Apr |
|
Activation of in vitro matured pig oocytes using activators of inositol triphosphate or ryanodine receptors. | 2002 Apr 15 |
|
Resonance Rayleigh scattering technology as a new method for the determination of the inclusion constant of beta-cyclodextrin. | 2002 Feb |
|
Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. | 2002 Feb |
|
[Tumescent technique for local anesthesia]. | 2002 Feb |
|
Effect of cholesterol liposomes on calcium mobilization in muscle cells from the rabbit sphincter of Oddi. | 2002 Feb |
|
Ionic basis of the resting membrane potential and action potential in the pharyngeal muscle of Caenorhabditis elegans. | 2002 Feb |
|
Recurrent corneal ulceration as late complication of toxic keratitis. | 2002 Feb |
|
Chloroprocaine is less painful than lidocaine for skin infiltration anesthesia. | 2002 Feb |
|
The inhibition of the N-methyl-D-aspartate receptor channel by local anesthetics in mouse CA1 pyramidal neurons. | 2002 Feb |
|
Improved right heart function after myocardial preservation with 2,3-butanedione 2-monoxime in a porcine model of allogenic heart transplantation. | 2002 Jan |
|
Short-acting peribulbar anesthesia with 2-chloroprocaine. | 2002 Jan |
|
Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryanodine receptor-dependent elevations of [Ca(2+)](I). | 2002 Jan 18 |
|
Allergy to local anaesthetics in dentistry. Myth or reality? | 2002 Jan-Feb |
|
Liver preservation with HTK: salutary effect of hypothermic aerobiosis by either gaseous oxygen or machine perfusion. | 2002 Jun |
|
Interaction of monosulfonate tetraphenyl porphyrin, a competitive inhibitor, with acetylcholinesterase. | 2002 Jun |
|
Non-surgical management of rectal tears in two mares. | 2002 Mar |
|
Biochemical and morphological changes in pancreas stored under hypothermic conditions. | 2002 Mar |
|
[Magnetically-guided anesthetics based on highly dispersed iron powders coated by polyacrylamide]. | 2002 Mar-Apr |
Sample Use Guides
Adults
Local or Regional Anesthesia
Local Infiltration
Usually, 350–600 mg, administered as diluted solution (i.e., 140–240 mL of a 0.25% solution or 70–120 mL of a 0.5% solution)
Peripheral Nerve Block
Up to 1 g, administered undiluted (i.e., 100 mL of a 1% injection) or as diluted solution (i.e., 200 mL of a 0.5% solution).
For local infiltration or peripheral nerve block, inject slowly and avoid rapid injection of large volumes; when feasible, administer in fractional (incremental) doses. For subarachnoid (spinal) block, use 2-mL single-dose ampuls containing procaine hydrochloride 10% only.c d Position patient properly prior to spinal anesthesia.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11812692
Procaine 0.2 mM reduced the maximal NMDA-induced currents without affecting the 50% effective concentration values for NMDA in mouse CA1 pyramidal neurons..
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:50 GMT 2023
by
admin
on
Fri Dec 15 14:59:50 GMT 2023
|
Record UNII |
7JFB7670YY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72941517
Created by
admin on Fri Dec 15 14:59:50 GMT 2023 , Edited by admin on Fri Dec 15 14:59:50 GMT 2023
|
PRIMARY | |||
|
7JFB7670YY
Created by
admin on Fri Dec 15 14:59:50 GMT 2023 , Edited by admin on Fri Dec 15 14:59:50 GMT 2023
|
PRIMARY | |||
|
17146-93-9
Created by
admin on Fri Dec 15 14:59:50 GMT 2023 , Edited by admin on Fri Dec 15 14:59:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |